Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H3NA
|
||||
| Former ID |
DNC003682
|
||||
| Drug Name |
4-Benzo[b]thiophen-4-yl-1H-imidazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [525720] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H8N2S
|
||||
| Canonical SMILES |
C1=CC(=C2C=CSC2=C1)C3=CN=CN3
|
||||
| InChI |
1S/C11H8N2S/c1-2-8(10-6-12-7-13-10)9-4-5-14-11(9)3-1/h1-7H,(H,12,13)
|
||||
| InChIKey |
QRRRICPYXPJYEH-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2B adrenergic receptor | Target Info | Inhibitor | [525720] | |
| Alpha-1A adrenergic receptor | Target Info | Inhibitor | [525720] | ||
| Alpha-1D adrenergic receptor | Target Info | Inhibitor | [525720] | ||
| Alpha-1B adrenergic receptor | Target Info | Inhibitor | [525720] | ||
| Alpha-2A adrenergic receptor | Target Info | Inhibitor | [525740] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| AMPK signaling pathway | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Salivary secretionhsa04020:Calcium signaling pathway | |||||
| Salivary secretionhsa04022:cGMP-PKG signaling pathway | |||||
| NetPath Pathway | IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | ||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors | |||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP58:Monoamine GPCRs | |||||
| Calcium Regulation in the Cardiac Cell | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Endothelin Pathways | |||||
| GPCR downstream signaling | |||||
| AMPK SignalingWP58:Monoamine GPCRs | |||||
| GPCRs, OtherWP58:Monoamine GPCRs | |||||
| Vitamin D Receptor Pathway | |||||
| Integration of energy metabolism | |||||
| References | |||||
| Ref 525720 | J Med Chem. 2000 Mar 9;43(5):765-8.alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a high-affinity ligand for the alpha(2D) adrenergic receptor. | ||||
| Ref 525740 | J Med Chem. 2000 Apr 6;43(7):1423-6.Alpha(2) adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-imidazo)-1,3-dimethyl-6,7-dihydro-thianaphthene as a high-affinity ligand for the alpha(2D) adrenergic receptor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.